MedTrace Logo

Optimizing Pazopanib Exposure in RCC Patients

NCT02089802 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-08-18

No results posted yet for this study

Summary

Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.

Conditions

  • Locally Advanced Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

Sponsors & Collaborators

  • OnkoDataMed GmbH

    collaborator INDUSTRY

  • Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.

    lead OTHER

Principal Investigators

  • Goetz Geiges, MD · IQUO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-25
Primary Completion
2016-03-22
Completion
2016-03-22

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02089802 on ClinicalTrials.gov